Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NANP | Q8TBE9 | 3/20 | 0.73 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CD22 | P20273 | 2/20 | 0.36 |
| ▸ | SIGLEC7 | Q9Y286 | 1/20 | 0.36 |
| ▸ | SELL | P14151 | 1/20 | 0.35 |
| ▸ | SELP | P16109 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27240372 | 1.00 | NANP (0.73) | NANPL3MBTL1CD22SIGLEC7SELL | |
| SCHEMBL987055 | 1.00 | NANP (0.73) | NANPL3MBTL1CD22SIGLEC7SELL | |
| SCHEMBL13191000 | 1.00 | NANP (0.73) | NANPL3MBTL1CD22SIGLEC7SELL | |
| SCHEMBL30887281 | 0.87 | NANP (0.69) | NANPL3MBTL1CD22SIGLEC7SELL | |
| SCHEMBL27240262 | 0.87 | NANP (0.69) | NANPL3MBTL1CD22SIGLEC7SELL | |
| Sialic Acid SCHEMBL29668416 | 0.86 | NANP (0.77) | NANPL3MBTL1SIGLEC7SELLSELP | |
| Sialic Acid SCHEMBL19718196 | 0.86 | NANP (0.77) | NANPL3MBTL1SIGLEC7SELLSELP | |
| Sialic Acid SCHEMBL3156058 | 0.86 | NANP (0.77) | NANPL3MBTL1SIGLEC7SELLSELP | |
| SCHEMBL420656 | 0.86 | NANP (0.67) | NANPL3MBTL1SELLSELP | |
| SCHEMBL29390472 | 0.86 | NANP (0.67) | NANPL3MBTL1SELLSELP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12582612-B2 | Pharmaceutical composition of Siglec-binding agents | CYTODIGM, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| EP-3962491-B1 | INTRACELLULAR DELIVERY OF ANTI-KRAS ANTIBODIES FORMULATED INTO NANOCAPSULES | UNIV SANTIAGO COMPOSTELA (ES) | 2025-08-06 | — | — | EP | disclosed |
| US-20250043253-A1 | SIALYLTRANSFERASES FOR THE PRODUCTION OF SIALYLATED OLIGOSACCHARIDES | INBIOSE N.V. (BE) | 2025-02-06 | — | — | US | disclosed |
| US-20240358653-A1 | NOVEL PARTICLE COMPOSITION COMPRISING SIALIC ACID BINDING LIGAND | CYTODIGM, INC. | 2024-10-31 | — | — | US | disclosed |
| EP-4448733-A1 | SIALYLTRANSFERASES FOR THE PRODUCTION OF SIALYLATED OLIGOSACCHARIDES | Inbiose N.V. (BE) | 2024-10-23 | — | — | EP | disclosed |
| EP-4448781-A1 | PRODUCTION OF ALPHA-1,4-FUCOSYLATED COMPOUNDS | Inbiose N.V. (BE) | 2024-10-23 | — | — | EP | disclosed |
| US-20240294958-A1 | EXTRACELLULAR PRODUCTION OF GLYCOSYLATED PRODUCTS | INBIOSE NV (BE) | 2024-09-05 | — | — | US | disclosed |
| US-20240294959-A1 | CELLULAR PRODUCTION OF BIOPRODUCTS | INBIOSE N.V. (BE) | 2024-09-05 | — | — | US | disclosed |
| US-20240189797-A1 | SEPARATION MEDIA AND PURIFICATION METHODS FOR CARBOHYDRATE BINDING DOMAIN CONTAINING MOLECULES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-13 | — | — | US | disclosed |
| US-20240190913-A1 | SEPARATION MEDIA AND PURIFICATION METHODS FOR CARBOHYDRATE CONTAINING MOLECULES USING THE SAME | DONALDSON COMPANY, INC. | 2024-06-13 | — | — | US | disclosed |
| WO-2022152915-A1 | EXTRACELLULAR PRODUCTION OF GLYCOSYLATED PRODUCTS | INBIOSE N.V. (BE) | 2022-07-21 | — | — | WO | disclosed |
| WO-2022129470-A1 | VARIANT SUCROSE PERMEASE POLYPEPTIDES | INBIOSE N.V. (BE) | 2022-06-23 | — | — | WO | disclosed |
| US-20220177603-A1 | INTRACELLULAR DELIVERY OF ANTI-KRAS ANTIBODIES FORMULATED INTO NANOCAPSULES | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2022-06-09 | — | — | US | disclosed |
| US-20220142948-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC REGULATORS OF T CELL PATHOGENICITY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2022-05-12 | — | — | US | disclosed |
| US-20220142935-A1 | PHARMACEUTICAL COMPOSITION OF SIGLEC-BINDING AGENTS | CYTODIGM, INC. | 2022-05-12 | — | — | US | disclosed |
| WO-2022076435-A1 | PHARMACEUTICAL COMPOSITION OF SIGLEC-BINDING AGENTS | PHOSPHOREX, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| EP-3962491-A1 | INTRACELLULAR DELIVERY OF ANTI-KRAS ANTIBODIES FORMULATED INTO NANOCAPSULES | Universidade De Santiago De Compostela (ES) | 2022-03-09 | — | — | EP | disclosed |
| WO-2022034076-A2 | PRODUCTION OF GALACTOSYLATED DI- AND OLIGOSACCHARIDES | INBIOSE N.V. (BE) | 2022-02-17 | — | — | WO | disclosed |
| WO-2022034075-A1 | PRODUCTION OF GLCNAC CONTAINING BIOPRODUCTS IN A CELL | INBIOSE N.V. (BE) | 2022-02-17 | — | — | WO | disclosed |
| WO-2022034077-A1 | PRODUCTION OF ALPHA-1,3 GLYCOSYLATED FORM OF FUC-A1,2-GAL-R | INBIOSE N.V. (BE) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240189797-A1 | SEPARATION MEDIA AND PURIFICATION METHODS FOR CARBOHYDRATE BINDING DOMAIN CONTAINING MOLECULES | CACYBP, MGAM, MASP2 | NANP 1105/4885L3MBTL1 2639/4885CD22 633/4885 |
| US-20240190913-A1 | SEPARATION MEDIA AND PURIFICATION METHODS FOR CARBOHYDRATE CONTAINING MOLECULES USING THE SAME | MGAM, MASP2, MGAM2 | NANP 282/4885L3MBTL1 4034/4885CD22 186/4885 |
| US-20220142935-A1 | PHARMACEUTICAL COMPOSITION OF SIGLEC-BINDING AGENTS | SIGLEC7, SIGLEC9, SELPLG | NANP 1206/4885L3MBTL1 4868/4885CD22 15/4885 |
| US-20240358653-A1 | NOVEL PARTICLE COMPOSITION COMPRISING SIALIC ACID BINDING LIGAND | SIGLEC9, SIGLEC7, SELPLG | NANP 65/4885L3MBTL1 3860/4885CD22 63/4885 |
| US-20220177603-A1 | INTRACELLULAR DELIVERY OF ANTI-KRAS ANTIBODIES FORMULATED INTO NANOCAPSULES | KRAS, NRAS, TP53 | NANP 3811/4885L3MBTL1 1735/4885CD22 2025/4885 |
| US-12582612-B2 | Pharmaceutical composition of Siglec-binding agents | SIGLEC7, SIGLEC9, CD2 | NANP 221/4885L3MBTL1 4101/4885CD22 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.